Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hepatitis C, Chronic | 9 | 2019 | 973 | 2.24 | Why? |
| Liver Cirrhosis | 8 | 2019 | 1810 | 1.97 | Why? |
| Pseudomonas Infections | 3 | 2018 | 425 | 1.48 | Why? |
| Penicillanic Acid | 2 | 2017 | 58 | 1.37 | Why? |
| Cephalosporins | 3 | 2018 | 250 | 1.31 | Why? |
| Pseudomonas aeruginosa | 4 | 2018 | 652 | 1.12 | Why? |
| Alemtuzumab | 2 | 2018 | 121 | 0.87 | Why? |
| Autism Spectrum Disorder | 2 | 2018 | 587 | 0.79 | Why? |
| Hepatitis C Antibodies | 1 | 2019 | 120 | 0.73 | Why? |
| Carcinoma, Hepatocellular | 2 | 2019 | 1222 | 0.69 | Why? |
| Herpesvirus 2, Human | 1 | 2018 | 137 | 0.68 | Why? |
| alpha-Fetoproteins | 1 | 2017 | 72 | 0.67 | Why? |
| Pyrophosphatases | 1 | 2017 | 39 | 0.66 | Why? |
| Erectile Dysfunction | 1 | 2018 | 141 | 0.65 | Why? |
| beta-Lactamase Inhibitors | 1 | 2017 | 104 | 0.64 | Why? |
| Azabicyclo Compounds | 1 | 2017 | 91 | 0.63 | Why? |
| Ceftazidime | 1 | 2017 | 134 | 0.61 | Why? |
| Liver Neoplasms | 2 | 2019 | 1666 | 0.61 | Why? |
| Hepatitis C | 2 | 2017 | 1514 | 0.61 | Why? |
| Osteomyelitis | 1 | 2017 | 131 | 0.60 | Why? |
| Post-Exposure Prophylaxis | 1 | 2020 | 472 | 0.59 | Why? |
| Herpesvirus 1, Human | 1 | 2018 | 286 | 0.58 | Why? |
| Herpes Simplex | 1 | 2018 | 272 | 0.57 | Why? |
| Drug Resistance, Multiple, Bacterial | 3 | 2017 | 1115 | 0.57 | Why? |
| Hepacivirus | 4 | 2019 | 1509 | 0.56 | Why? |
| Vitamin D Deficiency | 2 | 2019 | 1782 | 0.55 | Why? |
| Cytomegalovirus Infections | 2 | 2018 | 667 | 0.53 | Why? |
| Protein Precursors | 1 | 2017 | 425 | 0.51 | Why? |
| Genotype | 6 | 2021 | 4697 | 0.51 | Why? |
| Opportunistic Infections | 2 | 2018 | 602 | 0.48 | Why? |
| Bacterial Infections | 4 | 2018 | 2229 | 0.46 | Why? |
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 529 | 0.46 | Why? |
| Thyroidectomy | 1 | 2014 | 207 | 0.46 | Why? |
| Cytomegalovirus | 1 | 2017 | 600 | 0.45 | Why? |
| Hepatitis B, Chronic | 1 | 2018 | 616 | 0.45 | Why? |
| Urinary Tract Infections | 1 | 2017 | 534 | 0.45 | Why? |
| Peritonitis | 3 | 2018 | 217 | 0.45 | Why? |
| Fractures, Bone | 1 | 2017 | 487 | 0.44 | Why? |
| Antibiotic Prophylaxis | 1 | 2014 | 399 | 0.43 | Why? |
| Ribavirin | 1 | 2017 | 1182 | 0.39 | Why? |
| Anemia | 1 | 2017 | 789 | 0.39 | Why? |
| Hepatitis B | 1 | 2017 | 888 | 0.37 | Why? |
| Anti-Bacterial Agents | 4 | 2018 | 10083 | 0.36 | Why? |
| Communicable Diseases, Emerging | 2 | 2020 | 2523 | 0.36 | Why? |
| Venous Thrombosis | 1 | 2021 | 2739 | 0.30 | Why? |
| Antiviral Agents | 7 | 2020 | 41703 | 0.30 | Why? |
| Point-of-Care Testing | 1 | 2019 | 2782 | 0.30 | Why? |
| Genome, Viral | 2 | 2018 | 13157 | 0.30 | Why? |
| Dried Blood Spot Testing | 2 | 2018 | 383 | 0.27 | Why? |
| Prevalence | 9 | 2020 | 25773 | 0.26 | Why? |
| Italy | 13 | 2021 | 38444 | 0.25 | Why? |
| Saliva | 1 | 2019 | 4679 | 0.24 | Why? |
| B-Cell Activation Factor Receptor | 1 | 2021 | 33 | 0.23 | Why? |
| Fusobacterium | 1 | 2021 | 19 | 0.23 | Why? |
| Fusobacterium Infections | 1 | 2021 | 37 | 0.22 | Why? |
| Drug Therapy, Combination | 4 | 2019 | 7268 | 0.21 | Why? |
| Disease Management | 2 | 2020 | 6841 | 0.20 | Why? |
| Asymptomatic Infections | 1 | 2019 | 7218 | 0.20 | Why? |
| Receptors, CCR5 | 1 | 2021 | 186 | 0.20 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2017 | 5164 | 0.20 | Why? |
| N-Acetylneuraminic Acid | 1 | 2021 | 198 | 0.19 | Why? |
| Pneumocystis carinii | 1 | 2021 | 205 | 0.19 | Why? |
| Phosphodiesterase Inhibitors | 1 | 2018 | 61 | 0.18 | Why? |
| Mucin-1 | 1 | 2021 | 277 | 0.18 | Why? |
| Male | 27 | 2021 | 367725 | 0.18 | Why? |
| Middle Aged | 22 | 2021 | 270681 | 0.17 | Why? |
| Humans | 44 | 2021 | 930598 | 0.17 | Why? |
| Risk Factors | 8 | 2020 | 71621 | 0.16 | Why? |
| Aged | 17 | 2021 | 215776 | 0.16 | Why? |
| Prothrombin | 1 | 2017 | 149 | 0.16 | Why? |
| Pneumonia, Pneumocystis | 1 | 2021 | 322 | 0.16 | Why? |
| Gene Frequency | 2 | 2021 | 1210 | 0.15 | Why? |
| Lipid Metabolism | 1 | 2021 | 572 | 0.15 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.15 | Why? |
| Product Surveillance, Postmarketing | 1 | 2018 | 189 | 0.15 | Why? |
| Enzyme Activation | 1 | 2017 | 425 | 0.15 | Why? |
| Chemoprevention | 1 | 2020 | 585 | 0.15 | Why? |
| Female | 23 | 2021 | 380317 | 0.15 | Why? |
| Prospective Studies | 6 | 2020 | 43301 | 0.14 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.14 | Why? |
| Practice Patterns, Physicians' | 1 | 2014 | 4927 | 0.14 | Why? |
| Alleles | 2 | 2021 | 1557 | 0.14 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.14 | Why? |
| Parathyroid Glands | 1 | 2014 | 27 | 0.14 | Why? |
| Liver | 2 | 2019 | 4007 | 0.13 | Why? |
| Emergency Service, Hospital | 1 | 2019 | 14232 | 0.13 | Why? |
| Heparin, Low-Molecular-Weight | 2 | 2021 | 1731 | 0.13 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.13 | Why? |
| Disease-Free Survival | 1 | 2019 | 1654 | 0.13 | Why? |
| Fibrosis | 1 | 2017 | 800 | 0.13 | Why? |
| Ventricular Dysfunction, Right | 1 | 2020 | 639 | 0.13 | Why? |
| Multiple Sclerosis | 2 | 2020 | 2600 | 0.13 | Why? |
| Lymphocyte Subsets | 1 | 2020 | 987 | 0.13 | Why? |
| Survival Analysis | 4 | 2021 | 7592 | 0.13 | Why? |
| Vitamin D | 2 | 2019 | 2904 | 0.12 | Why? |
| Liver Function Tests | 1 | 2018 | 1325 | 0.12 | Why? |
| Flow Cytometry | 1 | 2020 | 2393 | 0.11 | Why? |
| Pneumonia, Bacterial | 1 | 2018 | 843 | 0.11 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.11 | Why? |
| Polymorphism, Single Nucleotide | 3 | 2021 | 3607 | 0.11 | Why? |
| Microbiota | 1 | 2021 | 1240 | 0.10 | Why? |
| Severity of Illness Index | 7 | 2021 | 48226 | 0.10 | Why? |
| Antitubercular Agents | 1 | 2017 | 775 | 0.10 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.10 | Why? |
| Feasibility Studies | 1 | 2019 | 3467 | 0.10 | Why? |
| Antimalarials | 1 | 2021 | 2505 | 0.09 | Why? |
| Thyroid Gland | 1 | 2014 | 516 | 0.09 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.09 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.09 | Why? |
| Thrombophilia | 1 | 2021 | 1935 | 0.09 | Why? |
| Hospital Mortality | 3 | 2021 | 22087 | 0.09 | Why? |
| Prognosis | 4 | 2021 | 32490 | 0.09 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.09 | Why? |
| Immunization | 1 | 2017 | 2019 | 0.09 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.08 | Why? |
| Anticoagulants | 2 | 2021 | 9563 | 0.08 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.08 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.08 | Why? |
| Pilot Projects | 1 | 2019 | 5182 | 0.08 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.08 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.08 | Why? |
| Genetic Predisposition to Disease | 1 | 2021 | 4027 | 0.08 | Why? |
| Proportional Hazards Models | 1 | 2019 | 6543 | 0.08 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.08 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.07 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.07 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.06 | Why? |
| Child, Preschool | 2 | 2018 | 36283 | 0.06 | Why? |
| Disease Susceptibility | 1 | 2017 | 4002 | 0.06 | Why? |
| Viral Nonstructural Proteins | 2 | 2018 | 4810 | 0.06 | Why? |
| Intensive Care Units | 3 | 2020 | 29594 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.06 | Why? |
| Chromosomes, Human | 1 | 2021 | 38 | 0.06 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.06 | Why? |
| Discriminant Analysis | 1 | 2021 | 170 | 0.05 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.05 | Why? |
| Least-Squares Analysis | 1 | 2021 | 254 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.05 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.05 | Why? |
| Immunocompetence | 1 | 2021 | 280 | 0.05 | Why? |
| Alarmins | 1 | 2021 | 180 | 0.05 | Why? |
| Surgeons | 1 | 2014 | 2233 | 0.05 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.05 | Why? |
| Heart Failure | 1 | 2020 | 6638 | 0.05 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.05 | Why? |
| Whole Exome Sequencing | 1 | 2021 | 437 | 0.05 | Why? |
| Lymphocyte Count | 2 | 2021 | 4758 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.05 | Why? |
| Venous Thromboembolism | 1 | 2017 | 4273 | 0.04 | Why? |
| Child | 2 | 2018 | 70012 | 0.04 | Why? |
| Methicillin | 1 | 2017 | 73 | 0.04 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Daptomycin | 1 | 2017 | 64 | 0.04 | Why? |
| Sustained Virologic Response | 1 | 2019 | 378 | 0.04 | Why? |
| Vancomycin-Resistant Enterococci | 1 | 2017 | 104 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Mouth | 1 | 2021 | 622 | 0.04 | Why? |
| Blood Coagulation | 2 | 2021 | 2768 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.04 | Why? |
| Databases, Genetic | 1 | 2021 | 1127 | 0.04 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.04 | Why? |
| Radiologists | 1 | 2021 | 873 | 0.03 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2017 | 801 | 0.03 | Why? |
| Vitamin K | 1 | 2017 | 263 | 0.03 | Why? |
| Bronchi | 1 | 2021 | 1048 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2020 | 1262 | 0.03 | Why? |
| Carbapenems | 1 | 2017 | 343 | 0.03 | Why? |
| Infant | 1 | 2017 | 30274 | 0.03 | Why? |
| Lipids | 1 | 2021 | 1079 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2021 | 1648 | 0.03 | Why? |
| Pulmonary Artery | 1 | 2020 | 803 | 0.03 | Why? |
| Critical Illness | 1 | 2017 | 17281 | 0.03 | Why? |
| Enterobacteriaceae | 1 | 2017 | 395 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Cluster Analysis | 1 | 2021 | 3001 | 0.03 | Why? |
| Mutation, Missense | 1 | 2018 | 863 | 0.03 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.03 | Why? |
| beta-Lactamases | 1 | 2017 | 759 | 0.03 | Why? |
| Amino Acid Substitution | 1 | 2018 | 1706 | 0.03 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 711 | 0.03 | Why? |
| Precision Medicine | 1 | 2020 | 1477 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.02 | Why? |
| Drug Interactions | 1 | 2017 | 1653 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2018 | 2830 | 0.02 | Why? |
| Lymphocytes | 1 | 2021 | 3056 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.02 | Why? |
| Echocardiography | 1 | 2020 | 3661 | 0.02 | Why? |
| Computational Biology | 1 | 2021 | 4514 | 0.02 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.02 | Why? |
| Community-Acquired Infections | 1 | 2018 | 2328 | 0.02 | Why? |
| Hospitals, University | 1 | 2018 | 4173 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.02 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Adult | 3 | 2021 | 244371 | 0.01 | Why? |
| Hospitals | 1 | 2017 | 11793 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2021 | 25144 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Lung | 1 | 2021 | 31049 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
Gentile's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(218)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(347)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_